PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Negative revenue growth while AVXL stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-148.93%
Negative gross profit growth while AVXL is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-24.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-23.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-23.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Negative 10Y OCF/share CAGR while AVXL stands at 28.76%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
89.77%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
79.09%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-5123.81%
Negative 10Y net income/share CAGR while AVXL is at 29.39%. Joel Greenblatt sees a major red flag in long-term profit erosion.
89.73%
5Y net income/share CAGR above 1.5x AVXL's 8.82%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
77.51%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1605.51%
10Y equity/share CAGR 1.25-1.5x AVXL's 1230.58%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
-64.94%
Negative 5Y equity/share growth while AVXL is at 1111.33%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
48.08%
Below 50% of AVXL's 342.17%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-26.37%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
15.04%
R&D growth drastically higher vs. AVXL's 4.55%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
33.15%
SG&A growth well above AVXL's 18.28%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.